MRD-driven phase 2 study of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2024 at "Blood Advances"
DOI: 10.1182/bloodadvances.2024014417
Abstract: Key Points • Dara-KRd–based, MRD-adapted treatment yielded high stringent CR rates and MRD negativity that improved over time.• Results support randomized studies of therapy de-escalation for patients who are MRD(-) and escalation for MRD(+) after… read more here.
Keywords: driven phase; daratumumab carfilzomib; phase study; carfilzomib lenalidomide ... See more keywords